At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
In Brief
A Phase 3 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, and 2 other interventions for Dry Eye. Completed, enrolled 422 participants across 1 site.
Detailed Summary
The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Study Details
Timeline
Interventions
Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
Vehicle Ophthalmic Solution administered QID for twelve weeks
Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks